A randomized placebo-controlled trial of arbaclofen vs. placebo in the treatment of children and adolescents with ASD
Read below to learn about an opportunity for children and youth between the ages of 5 and 17 with a diagnosis of autism spectrum disorder to participate in a study to find out if arbaclofen is helpful in improving social function.
The purpose of the study is to investigate a drug called arbaclofen to improve social functioning in children and teens with Autism.
Who can participate?
Children and teens between 5 and 17 years old
Diagnosed with an autism spectrum disorder (ASD, autism, PDD-NOS, or Asperger’s syndrome )
Able to tolerate bloodwork
The trial will last a total of 18 weeks (4.5 months) and involves taking either arbaclofen or a placebo, as a meltaway tablet, 1-3 times per day for 18 weeks. You and your child will first be asked to come in for a screening session; through talking with you and completing some assessments, we will determine if your child meets eligibility criteria.
Visits will occur at a participating site near you: Holland Bloorview, Queen’s University, McMaster University or Lawson Research Institute.Visits will take place every 2-4 weeks while your child is taking the drug or placebo.This study also has an optional continuation part, which means that all participants will be able to take arbaclofen at the end of the 18 weeks.The same tests and procedures will be followed that were followed during the main study.
Arbaclofen may help improve social functioning
This research will help other children and families with ASD
The most common side effects are sedation (tiredness) and upset stomach
Participants will receive a gift card at each visit to thank them for their time.
If you are interested in participating in this study or have questions please contact Leanne Ristic at 416-425-6220 ext. 6321 or email@example.com